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Objective:   
Service evaluation of GP access to Faecal Immunochemical Test (FIT) for colorectal cancer 
(CRC) detection in Nottinghamshire and use of FIT for “rule out”, “rule in” and “first test 
selection”. 
Design: 
Retrospective audit of FIT results, CRC outcomes and resource utilisation before and after 
introduction of FIT in Primary Care in November 2017. Data from the new pathway up to 
December 2018 was compared with previous experience. 
Results: 
Between November 2017 and December 2018, 6747 GP FIT test requests yielded 5733 FIT 
results, of which 4082 (71.2%) were <4.0µg Hb/g faeces, 579 (10.1%) were 4.0-9.9µg Hb/g 
faeces, 836 (14.6%) were 10.0-149.9µg Hb/g faeces, and 236 (4.1%) were ≥150.0µg Hb/g 
faeces. The proportion of “rule out” results <4.0µg Hb/g faeces was significantly higher than 
in the Getting FIT cohort (71.2% vs 60.4%, Chi squared 42.8, p<0.0001) and the proportion 
of “rule in” results ≥150.0µg Hb/g faeces was significantly lower ( 4.1% vs 8.1%, Chi 
squared 27.3,P<0.0001). 
There was a 33% rise in urgent referrals across Nottingham overall during the evaluation 
period. 2 CRC diagnoses were made in 4082 patients who had FIT<4.0µg Hb/g faeces.  
58.4% of new CRC diagnoses associated with a positive FIT were early stage cancers (Stage 
I and II). The proportion of all CRC diagnoses that follow an urgent referral s rose after 
introduction of FIT. 
Conclusions: 
FIT allows GP’s to select a more appropriate cohort for urgent investigation without a large 
number of missed diagnoses. FIT appears to promise a “stage migration” effect which may 
ultimately improve CRC outcomes. 
 




Cancer outcomes in the United Kingdom lag behind the rest of Europe despite nearly two 
decades of concerted effort1. Colorectal cancer (CRC), a common cancer diagnosis and cause 
of cancer death2, remains an area of concern. This is not surprising as current criteria for 
urgent referral to secondary care are largely based on age and symptoms3 – the latter are often 
associated with later stage disease and inherently non-specific. The Bowel Cancer Screening 
Programme (BCSP) has demonstrated that CRC is often asymptomatic4. Many individuals 
with CRC have vague symptoms and younger patients with symptoms are sometimes 
inappropriately reassured by the doctrine that CRC is a disease of the elderly. Furthermore, in 
the NHS significant diagnostic capacity is engaged investigating and re-investigating 
individuals with no identifiable cause for their symptoms, in whom health and wellbeing 
input might actually be more clinically effective. 
Segmentation and stratification of the Primary care population is key to improving early 
diagnosis for CRC. Simple measures such as a Full Blood Count (FBC) can identify markers 
such as anaemia5-7 and thrombocytosis8 that may have value. However, testing for occult 
blood in faeces – the basis of BCSP – currently holds much promise. Faecal 
Immunochemical Testing (FIT) is more sensitive and objective than Guaiac-based FOBT 
(gFOBT) and has been shown to be useful in patients with symptoms9-12. In 2015, NICE 
guidance opened the door to testing for occult blood in faeces  in low risk patients, without 
clearly defining which test should be used3.  In September 2016, we introduced a locally 
commissioned year-long pilot of FIT in our two week wait (2WW) population (excluding 
those with rectal bleeding) and demonstrated clear stratification value in all symptom 
groups9. In November 2017, we introduced a Rapid Colorectal Cancer Diagnosis (RCCD) 
Pathway incorporating direct General Practitioner (GP) access to FIT and use of FIT results 
for “rule in”, “rule out” and “first test” selection in secondary care13. We present an overview 
of the impact of GP access to FIT and RCCD on our local practice during the first year of this 
novel English pathway. 
 
Methods 
Rapid Colorectal Cancer Diagnosis Pathway (RCCD) 
This “locally agreed” pathway was designed to incorporate FIT as a triage tool for all referral 
criteria, except rectal bleeding and rectal mass, as described elsewhere13. GPs were able to 
request FIT (and blood tests) independently and act on the result, or if clinical suspicion was 
high they could submit an RCCD referral form contemporaneously. In the latter pathway, the 
form was held for 12 working days in a “window” and the 62 day clock only started either on 
receipt of FIT (and blood) results or on expiry of the “window”.  
FIT requests and testing 
FIT requests in Primary Care were made on an electronic request system (ICE) that also 
prompted requests for blood tests where indicated. Results were notified on the same 
electronic system with text guidance on how to interpret results and subsequent actions. An 
electronic guidance system F12 (SystemOne) was also used to guide GPs on the use of FIT 
and the new pathway in those practices that use this system, with direct links to the relevant 
referral form where appropriate. 
FIT dispatch and return was entirely postal and kits were analysed according to 
manufacturer’s protocols as described elsewhere9. 
“Rule in” 
Patients with a FIT result ≥150µg Hb/g faeces were considered “high risk” positive and the 
result was notified directly by BCSP to the Nottingham Colorectal Service STT team as well 
as to the GP, irrespective of whether an RCCD form had been submitted. This cut-off 
threshold was selected for our previous pilot as an approximate equivalent to a positive 
gFOBT – the only alternative in clinical practice at the time(9). The STT team contacted these 
patients directly for vetting and appropriate investigation on a “rapid” pathway according to 
local protocols. Patients with a result ≥10µg Hb/g faeces of a result ≥4µg Hb/g faeces in the 
presence of anaemia were also considered positive and were investigated on a two week wait 
(2WW) pathway. 
“Rule out” 
Patients with a FIT result <4µg Hb/g faeces were considered to have a “negative” FIT test 
and to be low risk for CRC. Patients with a FIT result ≥4 but <10µg Hb/g faeces were also 
considered “negative” if their Haemoglobin level was normal (≥130g/l in men; ≥120g/l in 
women). GP’s were advised that patients with negative FIT tests had low risk of CRC and 
management options were to consider an alternate urgent pathway, routine referral or repeat 
FIT testing. 
“First test” selection 
Patients with a “negative” FIT result in RCCD referrals for abdominal mass or weight loss 
were considered for Computerised Tomography (CT) with intravenous contrast. Patients with 
a “negative” FIT in RCCD referrals for Iron deficiency anaemia (IDA) were preferentially 
investigated with CT Colonography (CTC) rather than colonoscopy (with 
oesophagogastroduodenoscopy – OGD – if not undertaken recently). CTC was also chosen 
for patients who were frail, elderly or had other reasons to prefer non-invasive investigation 
as the first test (including patient choice). 
Patients referred with a rectal mass were not subject to FIT testing but were seen in a one-
stop flexible sigmoidoscopy clinic. Patients with rectal bleeding and no other symptoms and 
no anaemia were also seen in our one-stop clinic. Patients diagnosed with cancer in this one-
stop pathway could have CTC as part of their staging to exclude synchronous lesions if 
appropriate. 
Local providers 
Nottingham has two providers of urgent pathways for CRC. Historically, Nottingham 
University Hospitals NHS Trust saw 55.0% of two week wait (2WW) referrals and 
introduced Straight to test (STT) colonoscopy in August 2014 with prospective monitoring14. 
An independent provider (Circle Health, London, UK)) received 45.0% of referrals of 2WW 
referrals at a neighbouring Treatment Centre (TC). In each of these pathways, approximately 
55.0% of referrals did not mention rectal bleeding as a reason for referral. The TC did not 
adopt STT when introduced14, did not participate in the “Getting FIT” pilot9 and did not 
adopt the RCCD as described above. Additionally, FIT was not used in our local Upper 
Gastrointestinal Cancer 2WW pathways nor in 2WW upgrades from routine or emergency 
clinical settings during the evaluation period. 
Cohort and Data Collection 
All patients that were subject of a FIT request between 7th November 2017 and 31st 
December 2018 were logged prospectively in our BCSP hub in order to ensure clinical 
governance of this novel pathway. 
All patients referred to the Nottingham Colorectal Service STT team on an RCCD form 
between these dates were logged prospectively in our NUhCLEUS database that supports our 
STT pathway. Cancer Outcomes & Services Datasets (COSD) were used to evaluate 
diagnoses of CRC recorded using ICD codes C18-C20 (excluding C18.1 Appendix) with a 
censor date of 31st December 2018. NUH Trust data, electronic patient records and 
NUhCLEUS data were used for cross-checking and diagnosis data validation, as well as 
evaluation of diagnostics. Primary Care referral data was retrieved from Clinical 
Commissioning Groups (CCG’s) datasets. 
Data from our “Getting FIT” pilot9, historical COSD and NUhCLEUS data were also used 
for comparison. 
Statistical analysis 
Data were assessed for normality using histograms and a Shapiro-Wilk test.  Comparisons 
were made between continuous variables using the students t-test if normally distributed or 
Mann-Whitney if not normally distributed. Categorical data was summarised using 
frequencies and percentages. Comparisons were made between categorical data using Chi 
Squared tests. All statistics were performed using GraphPad Prism, GraphPad Software, San 
Diego, CA, USA. Tests of significance were considered significant if a P-value of less than 
0.05 was obtained.  
Funding 
The pathway was commissioned locally to allow direct access to FIT for local GPs and all 
four local CCGs (Nottingham City, Nottingham North and East, Nottingham West and 
Rushcliffe) approved and jointly funded this pathway. The cost of each FIT test was agreed 
as £17.50 per sample to CCGs – this included postage, analysis and administration costs. The 
cost of a “window” referral was £85 and the cost of a referral with all mandatory results 
available was £66 – to reflect the additional administrative work required to maintain the 
“window”.  
Results 
FIT requests and results 
6747 FIT test requests were made during the evaluation period (Figure 1a). 272 (4.0%) 
requests were rejected as clinic details mentioned rectal bleeding as a symptom. 92 (1.4%) 
duplicate requests were also received. 6383 kits were dispatched and 615 kits were not 
returned within 14 days (9.6%) and 35 kits were spoiled on return or not suitable for analysis 
(0.5%). 
5733 FIT results were available of which 4082 (71.2%) were <4 µg Hb/g faeces, 579 (10.1%) 
were 4-9.9 µg Hb/g faeces, 836 (14.6%) were 10.0-149.9 µg Hb/g faeces, and 236 (4.1%) 
were ≥150.0µg Hb/g faeces. The proportion of “rule out” results <4.0µg Hb/g faeces was 
significantly higher than in the two week wait population tested during our pilot9 (71.2% vs 
60.4%, Chi squared 42.8, p<0.0001) and the proportion of “rule in” results ≥150.0µg Hb/g 
faeces was significantly lower ( 4.1% vs 8.1%, Chi squared 27.3,P<0.0001) than in our pilot 
(Figure 1b). 
The number of FIT requests showed a steady rise throughout the evaluation period but with 
signs of more selective usage towards the end of the evaluation period (Figure 2a).  The 
demographics of patients who underwent FIT testing are shown in Table 1.  
Two week wait referrals 
Introduction of direct access to FIT and the Rapid Colorectal Cancer Diagnosis pathway was 
preceded by a dip in 2WW referrals to our Trust with an increase at the neighbouring TC 
(Figure 2b and c). However, this then reverted in early 2018 with a steady rise in referrals to 
the Trust pathway thereafter, but no significant change in referrals to the TC pathway where 
FIT was not implemented, yielding approximately 33% rise in referrals across Nottingham 
overall during the evaluation period. 
Diagnostic capacity and first test 
The numbers of monthly colonoscopy, flexible sigmoidoscopy and CT colon requests 
generated by the Trust 2WW pathway only are shown in Figure 3. There was a significant 
reduction in 2WW colonoscopy usage in the year after the introduction of FIT despite the rise 
in referrals when compared to the year prior to introduction (p=0.016, paired t test). 
Colonoscopy usage rose through the year and approached levels similar to the previous year 
towards the end the first year. We observed a corresponding significant increase in CTC 
activity as first test (p<0.01, Paired  t test). A significant increase in flexible sigmoidoscopy 
usage (p<0.01, Paired t test) was also evident but this change was not related to the use of 
FIT. 
Colorectal Cancer (CRC) diagnoses 
113 colorectal adenocarcinoma diagnoses were evident in patients who had been subject to a 
FIT request at the time of analysis.  4 (3.6%) patients did not receive a kit as rectal bleeding 
was a recorded symptom and 3 (2.7%) did not return their kit. 106 CRC diagnoses followed a 
FIT return, with 2 CRC diagnoses in 4082 patients with FIT results <4.0µg Hb/g faeces 
between November 2017 and 31st December 2018; one of which was a radiological diagnosis 
with no histological confirmation. 104 CRC diagnoses were recorded in 1285 patients with a 
positive FIT according to RCCD protocols - representing an overall detection rate of 8.1% 
(Table 2). 
101 new CRC diagnoses were made in this cohort and 3 diagnoses of recurrent luminal 
disease after previous treatment were also made.  In the new diagnosis group, 27 (26.7 %) 
were Stage I tumours and 32 (31.7%) were Stage II tumours (Table 2). Nearly half (12 of 26) 
Stage I CRC had a FIT result between 4.0 and 150.0µg Hb/g faeces.  
The overall number of CRC diagnoses made across both Nottingham pathways has risen 
compared to the previous year despite the use of FIT for “rule out” and “first test selection” 
in our Trust pathway (Figure 5). The number of cancers diagnosed on 2WW pathways in 
Nottingham has shifted significantly towards the Trust where FIT was used in this way 
(Figure 5). In diagnoses made at our Trust, the ratio or CRCs diagnosed after 2WW GP 
referral compared to CRC’s diagnosed after Routine GP referral shows a significant rise 
during the evaluation period.  
 
Discussion 
These data suggest a stage migration to early disease detection, with consequent 
improvement in clinical outcomes, may be achievable if FIT is used in all symptomatic 
patients. We have shown an increase in overall CRC detection rates and a significant shift 
towards 2WW diagnosis by introducing FIT in just one part of Nottingham’s 2WW services 
for symptomatic patients. We demonstrate that a symptomatic pathway incorporating FIT 
may be more clinically effective than one based on an arbitrary distinction between “high 
risk” and “low risk” groups as currently defined3. Our data also show that introduction of FIT 
in Primary Care broadens the population selected for assessment by GPs. This is 
demonstrated by the fact that the rate of negative FIT results (<4.0µg Hb/g faeces) is higher 
and the proportion of FIT results ≥150.0µg Hb/g faeces  is lower than that described in our 
2WW pathway pilot9. This was expected and represents inclusion of a lower risk population, 
in keeping with the intentions of NG12 when testing for occult blood in faeces was 
described3. This “opportunistic screening” probably underlies the trend towards earlier stage 
cancer that we observe in the cancers diagnosed on our Trust pathway and this is clearly the 
most promising aspect of FIT usage. The detection rate of 8.1% after a “positive” FIT at any 
level in patients without rectal bleeding is higher than we have demonstrated in previous 
evaluations7,13-14 suggesting improved clinical effectiveness overall. Current analysis suggests 
that introduction of FIT with a “rule out” contingency does not have a negative impact on 
diagnosis numbers. We acknowledge that further diagnoses of CRC after a FIT <4.0µg Hb/g 
faeces may yet come to light with longer follow-up.  
The reduction in demand on diagnostics after “rule out” is offset by increased use of FIT in 
the wider population prompting referrals in patients that may previously have been reassured. 
Thus, FIT has not reduced our 2WW pathway workload but simply changed the population 
we investigate. Therefore, it seems unlikely that FIT usage in symptomatic patients will 
create extra capacity in endoscopy unless higher thresholds are adopted, with consequent loss 
of sensitivity in symptomatic patients.  Alternatively, the use of FIT to identify lower risk 
patients that may be more suitable for CTC, as well as use in older frailer patients, might 
allow 2WW colonoscopy usage to fall despite increased referrals overall. We have not 
reported here on Routine investigation after FIT testing which would of course add further 
demand for diagnostic capacity. We have described 15.0% routine investigation rate after 
negative FIT elsewhere13, but it is important to note that this figure might have been higher if 
2WW referral had not been available at the TC (and for IDA via our UGI pathway). If 
introduction of FIT alone, at these very low thresholds for positivity, cannot create the 
colonoscopy capacity needed to allow lower thresholds in BCSP, scoring systems such as 
FAST15 with additional modifications for Hb, ferritin/iron and platelet levels, may allow 
improved positive predictive value for cancer in results between 4.0 and 150 .0g Hb/g 
faeces5-9. Such an approach, combined with a switch to CTC for lower risk patients might 
curb the rise in endoscopy demand.  
The follow up of those patients who were reassured after a FIT<4.0µg Hb/g faeces in this 
cohort remains short but consistent with other pathways using FIT in symptomatic patients16. 
The current data in Nottingham shows a low miss rate that may be unpalatable to the 
individual but is probably acceptable at a population level in a resource limited healthcare 
system. In the context, of increasing diagnoses on the most appropriate pathway and a shift 
towards early stage cancer diagnosis the overall benefit appears to outweigh the risk. In 
addition, if FIT is deemed a “reasonable” first test the impact on valid consent17 prior to 
colonoscopy is significant, especially in the unfortunate event of subsequent iatrogenic harm. 
Finally, increasing the number of cancers overall, the proportion diagnosed at early stage and 
the proportion diagnosed on 2WW pathways increases the number of patients that have to be 
treated within 62 days. This does have a negative impact on political targets for therapeutic 
services that are already full to bursting. Increased capacity for surgery and oncology may be 
required, alongside changes to diagnostic capacity as described above.  In light of the limited 
benefit, if any, of treating CRC within 62 days of diagnosis18-19, a political shift that promotes 
introduction of FIT over 62 day performance for CRC, may be a timely incentive for care 
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Table 1. Demographics of all patients undergoing FIT requests, all patients with a FIT result and patients stratified by FIT result. 

































Mean Age (y) 

























Table 2 Colorectal cancer detection rates and Stage of cancers in patients with FIT results. *Patients tested towards the end of the evaluation period may not 
have completed investigations or diagnoses may not have been recorded in Cancer Outcomes and Services Dataset (COSD) by the censor date of 31/12/18 – 
therefore these numbers shall rise in time. ~Not all patients were referred for investigation as per Rapid Colorectal Cancer Pathway protocols.  




FIT 4.0-9.9µg Hb/g 
faeces with anaemia 
FIT 4.0-9.9µg Hb/g 
faeces without anaemia 
FIT<4.0µg Hb/g 
faeces 
Patients 5733 236 836 213 366 4082 
Colorectal cancers detected post 
FIT* 
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Figure 1 a) Flow diagram of patients with FIT requests from referral to Colorectal Cancer 
(CRC) diagnosis. (Hb – Haemoglobin)      
        





















5733 FIT results 
6747 FIT requests 
 6383 FIT kits despatched 
272 rejected for rectal bleeding: 4 CRC diagnosed 
92 Duplicate requests 
615 kits not returned in 14 days: 3 CRC diagnosed 
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236 results 





Figure 1b) Comparison of FIT result breakdown during “Keeping FIT” (November 2017 – December 
2018) and “Getting FIT” pilot (September 2016- August 2017)9 by results strata: <4.0µg Hb/g faeces, 
4.0-9.9µg Hb/g faeces, 10.0-149.9µg Hb/g faeces and ≥150.0µg Hb/g faeces. The proportion results 
<4.0µg Hb/g faeces was significantly higher (71.2% vs 60.4%, Chi squared 42.8, p<0.0001) and the 
proportion of “rule in” results ≥150.0µg Hb/g faeces was significantly lower (4.1% vs 8.1%, Chi 
















Figure 2a) Rising trend of FIT requests received during the evaluation period. 
 
 
Figure 2b) Number of two week wait referrals received across both pathways in Nottingham from 






Figure 2c) Two week wait referrals from April 2016 to October 2018 by provider:  Nottingham 
University Hospitals NHS Trust using FIT (and Straight to test) as described and Nottingham 





Figure 3 Two week wait (2WW) colonoscopy, flexible sigmoidoscopy and CT colonography requests 
generated after a Rapid Colorectal Cancer Diagnosis pathway referral to Nottingham University 
Hospitals NHS Trust or FIT result ≥150.0µg Hb/g faeces only.  Activity for November 2017 – 
October 2018 “Keeping FIT” is compared with the preceding year (November 2016 – October 2017) 
prior to pathway introduction. 2WW requests from other sources and requests at Nottingham 
Treatment Centre are not shown as FIT was not used in these pathways. 
3a) Significant reduction in colonoscopy requests in 2017-18 compared to previous year (p=0.016, 
paired t test). 
 
3b) Significant increase in flexible sigmoidoscopy requests in 2017-18 compared to previous year 































































































Figure 4a The number of colorectal cancers diagnosed in Nottingham continues to rise despite the 
“rule out” mechanism adopted in symptomatic patients, with a rise in diagnoses associated with GP 
referral as well as other routes. 
 
Figure 4b Significant rise in the proportion of all Nottingham CRC diagnoses made after a Two week 
wait referral to Nottingham University Hospitals NHS Trust (NUH) compared to Nottingham 
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TC
NUH
 Figure 5 Ratio of CRC diagnoses made at Nottingham University Hospitals NHS Trust after an 
urgent referral to those made after a routine referral from November 2016 to October 2018). Ratio 
below 1 indicates more diagnoses made on routine pathways and Ratio above 1 indicates more 
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Appendix 
FIT testing process – additional detail for FITTER checklist: 
All patients referred without rectal bleeding were sent (by normal UK Post Office mail system) a 
faecal sample collection device (OC-Sensor™, Eiken Chemical Co, Tokyo, Japan) within 2 days of 
the 2WW referral being received. The haemoglobin concentration in the OC-Sensor FIT is determined 
in nanograms of haemoglobin per millilitre of buffer in the sample tube (ng/ml). Each sample tube 
contains 2 ml of stabilising sample buffer in which, with the aid of the test-wand, 10 mg of stool 
sample is suspended. Final results are reported in µg Hb/g faeces. 
The device was pre-labelled with the patient’s name, NHS number, a unique laboratory ID number 
and a space to add the sample date. An instruction leaflet for using the sampling device, a letter 
outlining the purpose of the test and clarifying that the results would not be used for diagnostic 
purposes in isolation, and a prepaid first class return envelope were also included. Participants were 
asked to sample their faeces according to instructions, date the sampling device, and return it to the 
laboratory as soon as possible within 14 days of receipt of the letter. The process for kit dispatch and 
return was entirely postal.  
All returned samples were logged prospectively at the receiving laboratory and analysed once for f-
Hb using the automated OC-Sensor™-iO (Eiken Chemical Co., Tokyo, Japan) according to 
manufacturer’s protocols, alongside f-Hb controls. The analyser was calibrated once a month, and 2 
levels of controls were validated at the beginning and end of each run. Returned samples were stored 
in a refrigerator at 4°C upon arrival until analysis. All samples were analysed within 1 week of 
receipt.  
If sample values were above the linearity of the assay (200µg Hb/g faeces) they were diluted in OC 
Calibration Diluent (1 in 10 and 1 in 100) in order to obtain a quantitative result.  
The manufacturer’s quoted limit of quantitation for the OC-sensor iO is 4.0µg Hb/g faeces with limit 
for detection as 2.0µg Hb/g faeces. The LOQ was also confirmed locally following analysis of  a) 
spiked diluted patient samples, n=50 (sample average of 4.4µg Hb/g faeces,  CV = 10.5%); and b) 
repeated measurements (n=6-11) of 5 independent patient samples (47 measurements) who had a 
mean f-Hb level of between 4.0 and 5.0µg Hb/g faeces and mean CV of 9.0%  
Analyses were carried out in our laboratories located at the Eastern Bowel Cancer Screening Hub, 
Nottingham, England. These laboratories are UKAS (The United Kingdom Accreditation Service) 
accredited (ISO 15189) and take part in the UK NEQAS (The United Kingdom National External 
Quality Assessment Service) external quality assessment schemes.  
All results were automatically uploaded to an electronic reporting system that communicated with 
both primary and secondary care electronic results systems. In addition, high readings FIT ≥150.0µg 
Hb/g faeces were notified by email to the Nottingham Colorectal Service STT team weekly, for direct 
contact as agreed in the new pathway. Laboratory staff was not involved in any clinical assessment or 
investigations and were therefore blinded to outcomes. 
 
